Glycomics/Glycobiology Segmentation
Product (Enzymes, Kits & Reagents, Instruments)
Based on product, the kits & reagents segment is expected to hold the highest share of 38.8% in the glycomics/glycobiology market by the end of 2037. The dominance of the segment is responsible for its increased applications in cancer and infectious disease screening procedures, and growing adoption in diagnostic labs. In this regard, NCEZID reported that there is a 25% increase in the volume of diagnostic testing in 2024, reflecting a positive market demand. Besides, the U.S. FDA states that in 2023 alone, 14 new glycan analysis kits were approved, which is a 42% increase since 2022. The regulatory support, coupled with diagnostic applications, reinforces dominance in the segment.
Application (Drug Discovery & Development, Diagnostics, Therapeutics)
Based on the application, the drug discovery and development segment is projected to account for a lucrative share of 34.6% in the glycomics/glycobiology market during the forecast period. The growth in the segment is subject to increased public healthcare investments. In this regard, NIH in 2024 reported that it allocated USD 670 million for glycan drug development, with more than 60% towards glycosylation engineering of biologic therapeutics. Besides, the approval of 80% of new biologics requires glycan analysis for characterization protocols, thus increasing the demand for glycobiology products.
Our in-depth analysis of the glycomics/glycobiology market includes the following segments:
|
Product |
|
|
Application |
|
|
End User |
|
